• KSII Transactions on Internet and Information Systems (TIIS)
• /
• v.14 no.8
• /
• pp.3420-3436
• /
• 2020

Due to the increasing number of malicious software (also known as malware), methods for sharing threat information are being studied by various organizations. The Malware Attribute Enumeration and Characterization (MAEC) format of malware is created by analysts, converted to Structured Threat Information Expression (STIX), and distributed by using Trusted Automated eXchange of Indicator Information (TAXII) protocol. Currently, when sharing malware analysis results, analysts have to manually input them into MAEC. Not many analysis results are shared publicly. In this paper, we propose an automated MAEC conversion technique for sharing analysis results of malicious Android applications. Upon continuous research and study of various static and dynamic analysis techniques of Android Applications, we developed a conversion tool by classifying parts that can be converted automatically through MAEC standard analysis, and parts that can be entered manually by analysts. Also using MAEC-to-STIX conversion, we have discovered that the MAEC file can be converted into STIX. Although other researches have been conducted on automatic conversion techniques of MAEC, they were limited to Windows and Linux only. In further verification of the conversion rate, we confirmed that analysts could improve the efficiency of analysis and establish a faster sharing system to cope with various Android malware using our proposed technique.

• Proceedings of the KAIS Fall Conference
• /
• 2007.11a
• /
• pp.71-73
• /
• 2007

본 논문은 질화갈륨 전력 소자를 이용한 이동통신 중계기 및 기지국용 전력증폭기 모듈의 설계에 대하여 기술하고 있다. 전력 버짓 분석을 통하여 전치증폭기와 구동증폭기, 그리고 최종단 고출력증폭기의 전력 용량을 계산하였고, 여기에 적합한 질화갈륨 소자를 선택하였다. 최종 개발에 앞선 초기버젼의 전력증폭기를 구성하여 1-tone과 2-tone에 대하여 전력특성을 측정해 보았다.

• Korean Journal of Clinical Pharmacy
• /
• v.34 no.1
• /
• pp.39-61
• /
• 2024

Background: The Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Ministry of Food and Drug Safety (MFDS) have been implementing the expedited programs that promote the innovative approval of new medications to be used for serious diseases. The authors comprehensively investigated, analyzed, and compared the regulations and guidelines associated with the expedited programs. Methods: The expedited programs for innovative drug development and approval were searched from the homepages of FDA, EMA and MFDS. The detailed information on the regulations and guidelines associated with the programs was comprehensively extracted from various electronic repositories of each regulatory authority. The information on each program was analyzed, categorized, and compared from the points of benefits, applicability with scientific rationale, application procedure, and maintenance. Results: FDA's programs include Fast Track Designation, Breakthrough Therapy Designation, Priority Review Designation, and Accelerated Approval. EMA's regulation implements PRIority MEdicines (PRIME), Accelerated Assessment, Marketing Authorization under Exceptional Circumstances (MAEC), and Conditional Marketing Authorization (CMA). MFDS has a single Expedited Program. These programs are broadly categorized into those that 1) facilitate early and proactive communication with regulatory authorities, 2) shorten the review time after submitting a marketing application, and 3) temporarily approve a marketing authorization under certain conditions. Conclusion: Each expedited program requires a different level and amount of safety and efficacy evidence to be submitted to each regulatory authority. This article will likely provide the comprehensive information on which program provides scientific and regulatory advantages to be taken for innovative medication development.

• The Journal of Internal Korean Medicine
• /
• v.18 no.2
• /
• pp.332-357
• /
• 1997

The purpose of study is for the defining the diagnostic criteria of Jung-Pung (中風) which are confused or unclear partially or Oriental Medicine. The results were obstained as follows ; 1. The Diagnosis of Jung-Pung (中風) can be accomplished by the name of disease, symptomatic classification, Byun-Jeung (辨證), stage, assessment of neurological deficit. 2. The various expressive way on the names of Jung-Pung (中風) can be unified as Jung-Pung (中風). 3. The symptomatic classification of Jung-Pung (中風) can be Jung-Kyung-Rak (中經絡) and Jung-Jang-Bu (中臟腑) by unconsciousness. 4. The subclassification of Jung-Kyung-Rak(中經絡) is Kanyangpokhang Punghwa sangyo (肝陽暴亢 風火上擾證), PungDamErHyul BiJoMaecRak (風痰瘀血 痺阻脈絡證), DamYeolBusil PoongDamSangYo (痰熱腑實 風痰上擾證), KiHerhyulEr (氣虛血瘀證), YeumHer PungDong (陰虛風動證) and Jung-Jang-Bu (中臟腑) is PungHwa SangYo CheongGeu (風火上擾淸竅證), DamSeupMongSac ShimSin (痰濕蒙塞心神證), DamYeolNaeFe ShimGeu (痰熱內閉心竅證), WonKiFaeTal ShimSinChakRan(元氣敗脫心神錯亂證) 5. The classification of stages can be divided as stroke stage, convalescent stage, complicated deficit stage. 6. In Oriental Medicine there were few assessment methods of neurological deficit. Therefore we need to develop new assessment system or modification of Western Medicine. The Standardization in the diagnosis of Jung-Pung (中風) has not been well established, even though we had have many clinical experiences. So it is necessary to make a accurate diagnosis that can be done by multiple diagnostic assessment. Therefore the accurate diagnosis of Jung-Pung (中風) can be done by 5 factors, they are the name of diagnosis, symptomatic classification, Byun-Jeung (辨證), stage, the assessment of neurological dificit. And it can be applied in the planning of treatment.